A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

Machine learning (ML) may harbor the potential to capture the metabolic complexity in Alzheimer Disease (AD). Here we set out to test the performance of metabolites in blood to categorize AD when compared to CSF biomarkers.

[1]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[2]  O. Fiehn.  Metabolomics – the link between genotypes and phenotypes , 2004, Plant Molecular Biology.

[3]  L. Ellegård,et al.  Metabolic profiles from two different breakfast meals characterized by 1H NMR-based metabolomics. , 2017, Food chemistry.

[4]  E. Green,et al.  The Influence of Nicotinamide on Health and Disease in the Central Nervous System , 2018, International journal of tryptophan research : IJTR.

[5]  David S. Wishart,et al.  MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis , 2018, Nucleic Acids Res..

[6]  Michelle K. Lupton,et al.  Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis , 2017, Alzheimer's & Dementia.

[7]  P. Sham,et al.  Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease , 2015, Translational Psychiatry.

[8]  Igor Kononenko,et al.  Estimating Attributes: Analysis and Extensions of RELIEF , 1994, ECML.

[9]  C. Legido-Quigley,et al.  Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease. , 2011, Bioanalysis.

[10]  K. Blennow,et al.  Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort , 2019, Alzheimer's & Dementia.

[11]  Trevor Hastie,et al.  The elements of statistical learning. 2001 , 2001 .

[12]  Daniel Stahl,et al.  Identifying psychosis spectrum disorder from experience sampling data using machine learning approaches , 2019, Schizophrenia Research.

[13]  Xianlin Han,et al.  Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome , 2018, Alzheimer's & Dementia.

[14]  Eric R. Ziegel,et al.  The Elements of Statistical Learning , 2003, Technometrics.

[15]  Xianlin Han,et al.  Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry , 2001, Journal of neurochemistry.

[16]  Michael W. Weiner,et al.  Metabolic network failures in Alzheimer's disease: A biochemical road map , 2017, Alzheimer's & Dementia.

[17]  Max Kuhn,et al.  Applied Predictive Modeling , 2013 .

[18]  Tianqi Chen,et al.  XGBoost: A Scalable Tree Boosting System , 2016, KDD.

[19]  R. Dobson,et al.  The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics , 2018, Alzheimer's Research & Therapy.

[20]  G. Reiser,et al.  Brain Lipotoxicity of Phytanic Acid and Very Long-chain Fatty Acids. Harmful Cellular/Mitochondrial Activities in Refsum Disease and X-Linked Adrenoleukodystrophy , 2016, Aging and disease.

[21]  Stephen Todd,et al.  A practical computerized decision support system for predicting the severity of Alzheimer’s disease of an individual , 2019, bioRxiv.

[22]  Fionn Murtagh,et al.  A Machine Learning Framework for Predicting Dementia and Mild Cognitive Impairment , 2018, 2018 17th IEEE International Conference on Machine Learning and Applications (ICMLA).

[23]  A. Saykin,et al.  Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study , 2018, PLoS medicine.